Neogen (NEOG) Free Cash Flow Growth (1y) (2011 - 2026)
Neogen (NEOG) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -109.40% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 363.84% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -31.71% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 133.09% |
| 10 | Neogen | 2.03 Bn | 1.87 Bn | 99.00 Mn | 182.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 182.34% |
| Nov 30, 2025 | -66.34% |
| Aug 31, 2025 | 76.66% |
| May 31, 2025 | -86.00% |
| Feb 28, 2025 | 78.42% |
| Nov 30, 2024 | 365.41% |
| Aug 31, 2024 | -639.36% |
| May 31, 2024 | -96.19% |
| Feb 29, 2024 | -93.44% |
| Nov 30, 2023 | 71.78% |
| Aug 31, 2023 | 71.92% |
| May 31, 2023 | 733.70% |
| Feb 28, 2023 | -49,469.23% |
| Nov 30, 2022 | -321.70% |
| Aug 31, 2022 | -223.84% |
| May 31, 2022 | -46.40% |
| Feb 28, 2022 | -101.97% |
| Nov 30, 2021 | -10.54% |
| Aug 31, 2021 | 4.93% |
| May 31, 2021 | -18.15% |